<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Gregory Glass | gregoryglass | Activity</title>
	<link>https://fdapetitions.com/members/gregoryglass-d27/activity/</link>
	<atom:link href="https://fdapetitions.com/members/gregoryglass-d27/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for gregoryglass.</description>
	<lastBuildDate>Thu, 19 Mar 2026 12:59:42 +0000</lastBuildDate>
	<generator>https://buddypress.org/?v=</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">bed00d3a5944dda77c77f1bf459ea860</guid>
				<title>gregoryglass started the topic Protonix®(pantoprazole) DR Oral Suspension in the forum Suitability Petitions</title>
				<link>https://fdapetitions.com/forums/topic/protonix-pantoprazole-dr-oral-suspension/</link>
				<pubDate>Mon, 25 Nov 2019 18:45:54 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Protonix®(pantoprazole) Delayed-release Oral Suspension</b><br />
<b>Company: </b> Wyeth<br />
<b>Petition Filer: </b> Foley Lardner, a law firm<br />
<b>Petition Number(s): </b> 2019P-5535<br />
<b>Date of First Petition: </b> November 22, 2019<br />
<b>Responding Petitions: </b> None</p>
<p><b>Action Requested of Petition: </b> The Petitioner is requesting the FDA to allow the manufacture of an oral&hellip;<span class="activity-read-more" id="activity-read-more-1290"><a href="https://fdapetitions.com/forums/topic/protonix-pantoprazole-dr-oral-suspension/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">0e6ff4e3664981bd0c0d123f56fac411</guid>
				<title>gregoryglass started the topic Penicillamine Capsules in the forum Product Petitions Archives</title>
				<link>https://fdapetitions.com/forums/topic/penicillamine-capsules/</link>
				<pubDate>Wed, 20 Nov 2019 18:55:54 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Penicillamine Capsules</b><br />
<b>Company: </b> Apicore<br />
<b>Petition Filer: </b> Apicore<br />
<b>Petition Number(s): </b> 2019P-5463 and 2019P-5571<br />
<b>Date of Petition: </b> November 20, 2019<br />
<b>Responding Petitions: </b></p>
<p><b>Issue and Implication:</b> Whether current FDA standards are sufficient to ensure bioequivalence.</p>
<p><b>Action Requested by Petitioner: </b> Petitioner is asking FDA to&hellip;<span class="activity-read-more" id="activity-read-more-1128"><a href="https://fdapetitions.com/forums/topic/penicillamine-capsules/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">38bf6efe29bb09999f36dc4369c2b231</guid>
				<title>gregoryglass started the topic Polymyxin B Sulfate Injection in the forum Product Petitions Archives</title>
				<link>https://fdapetitions.com/forums/topic/polymyxin-b-sulfate-injection/</link>
				<pubDate>Wed, 20 Nov 2019 18:41:55 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Polymyxin B Sulfate Injection</b><br />
<b>Company: </b> Various, Xellia<br />
<b>Petition Filer: </b> Hyman Phelps, a law firm<br />
<b>Petition Number(s): </b> 2019P-5441<br />
<b>Date of Petition: </b> November 19, 2019<br />
<b>Responding Petitions: </b></p>
<p><b>Issue and Implication:</b> Whether FDA must designate a second Reference Standard.</p>
<p><b>Action Requested by Petitioner: </b> Petitioner is requesting&hellip;<span class="activity-read-more" id="activity-read-more-1127"><a href="https://fdapetitions.com/forums/topic/polymyxin-b-sulfate-injection/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">2a441cd3daa965a606b68e9635cc598b</guid>
				<title>gregoryglass started the topic Augmentin XR®(amoxicillin and clavulanate) Extended-release Tablets in the forum Product Petitions Archives</title>
				<link>https://fdapetitions.com/forums/topic/augmentin-xr-amoxicillin-and-clavulanate-extended-release-tablets/</link>
				<pubDate>Thu, 07 Nov 2019 13:38:11 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Augmentin XR®(amoxicillin and clavulanate) Extended-release Tablets</b><br />
<b>Company: </b> Neopharma<br />
<b>Petition Filer: </b> Aurobindo<br />
<b>Petition Number(s): </b> 2019P-5237<br />
<b>Date of Petition: </b> November 6, 2019<br />
<b>Responding Petitions: </b></p>
<p><b>Issue and Implication:</b> Whether FDA must designate a second Reference Standard.</p>
<p><b>Action Requested by Petitioner: </b> Petitioner&hellip;<span class="activity-read-more" id="activity-read-more-1126"><a href="https://fdapetitions.com/forums/topic/augmentin-xr-amoxicillin-and-clavulanate-extended-release-tablets/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">f996d3e8d968003c17b4eb257e2eb3b0</guid>
				<title>gregoryglass started the topic GlucaGen®(glucagon) Injection in the forum Product Petitions</title>
				<link>https://fdapetitions.com/forums/topic/glucagen-glucagon-injection/</link>
				<pubDate>Fri, 25 Oct 2019 14:28:57 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: GlucaGen®(glucagon) Injection</b> <b>Company: </b> Fresenius Kabi/Novo Nordisk<b>Petition Filer: </b> Fresenius Kabi<b>Petition Number(s): </b> 2019P-4962<b>Date of Petition: </b> October 24, 2019<b>Responding Petitions: </b> <b>Issue and Implication:</b> Whether a 505(b)(2) NDA product merits an “A” rating with a similar drug.<b>Action Requested by Petitioner: </b> The Petitioner is aski&hellip;<span class="activity-read-more" id="activity-read-more-1125"><a href="https://fdapetitions.com/forums/topic/glucagen-glucagon-injection/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">5abf13d2724b36b48db9ab9d56c21c49</guid>
				<title>gregoryglass started the topic Diastat®(diazepam) Rectal Gel and Valtoco®(diazepam) Intranasal Solution in the forum Product Petitions Archives</title>
				<link>http://fdapetitions.com/forums/topic/diastat-diazepam-rectal-gel-and-valtoco-diazepam-intranasal-solution/</link>
				<pubDate>Fri, 18 Oct 2019 19:41:37 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Diastat®(diazepam) Rectal Gel and Valtoco®(diazepam) Intranasal Solution </b><br />
<b>Company: </b> Bausch Health/Neurelis<br />
<b>Petition Filer: </b> Aquestive<br />
<b>Petition Number(s): </b> 2019P-4832 and 2019P-5121<br />
<b>Date of Petition: </b> October 17, 2019 and November 4, 2019<br />
<b>Responding Petitions: </b> Neurelis</p>
<p><b>Issue and Implication:</b> Whether the Orphan Drug Act and c&hellip;<span class="activity-read-more" id="activity-read-more-1124"><a href="http://fdapetitions.com/forums/topic/diastat-diazepam-rectal-gel-and-valtoco-diazepam-intranasal-solution/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">aff826de03fffb15b780da77a43701de</guid>
				<title>gregoryglass started the topic Somatuline® Depot (lanreotide) Injection in the forum Product Petitions</title>
				<link>https://fdapetitions.com/forums/topic/somatuline-depot-lanreotide-injection/</link>
				<pubDate>Fri, 18 Oct 2019 19:23:45 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Somatuline® Depot (lanreotide) Injection</b><br />
<b>Company: </b> Ipsen SA<br />
<b>Petition Filer: </b> Ipsen SA<br />
<b>Petition Number(s): </b> 2019P-4830<br />
<b>Date of Petition: </b> October 17, 2019<br />
<b>Responding Petitions: </b></p>
<p><b>Issue and Implication:</b> Whether current FDA regulations are sufficient to ensure bioequivalence.</p>
<p><b>Action Requested by Petitioner: </b> The Petitioner is&hellip;<span class="activity-read-more" id="activity-read-more-1123"><a href="https://fdapetitions.com/forums/topic/somatuline-depot-lanreotide-injection/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">950f6ee688414e89df0bf1eb3610cbd3</guid>
				<title>gregoryglass started the topic Jatenzo®(testosterone) Capsule and Testosterone-ester prodrugs in the forum Product Petitions</title>
				<link>https://fdapetitions.com/forums/topic/jatenzo-testosterone-capsule-and-testosterone-ester-prodrugs/</link>
				<pubDate>Fri, 11 Oct 2019 14:36:50 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Jatenzo®(testosterone) Capsule and Testosterone-ester prodrugs</b> <b>Company: </b> Clarus Therapeutics<b>Petition Filer: </b> Clarus Therapeutics<b>Petition Number(s): </b> 2019P-4644<b>Date of Petition: </b> October 10, 2019<b>Responding Petitions: </b> <b>Issue and Implication:</b> Whether FDA must create and publish guidance for clinical study criteria for a class of&hellip;<span class="activity-read-more" id="activity-read-more-1122"><a href="https://fdapetitions.com/forums/topic/jatenzo-testosterone-capsule-and-testosterone-ester-prodrugs/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">49dae6741f2f071b68b4902585404657</guid>
				<title>gregoryglass started the topic Makena®(hydroxyprogesterone) Injection in the forum Product Petitions</title>
				<link>https://fdapetitions.com/forums/topic/makena-hydroxyprogesterone-injection/</link>
				<pubDate>Wed, 09 Oct 2019 14:42:32 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Makena®(hydroxyprogesterone) Injection</b><br />
<b>Company: </b> AMAG Pharma and various<br />
<b>Petition Filer: </b> Public Citizen<br />
<b>Petition Number(s): </b> 2019P-4683<br />
<b>Date of Petition: </b> October 8, 2019<br />
<b>Responding Petitions: </b> AMAG Pharma</p>
<p><b>Issue and Implication:</b> Whether FDA approval is sufficient to ensure the safe use and efficacy of any product.</p>
<p><b>Action&hellip;</b><span class="activity-read-more" id="activity-read-more-1121"><a href="https://fdapetitions.com/forums/topic/makena-hydroxyprogesterone-injection/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">6bf8482af3ff815e3c01d78558e13b9c</guid>
				<title>gregoryglass started the topic Vesicare®(solifenacin) Orally Disintegrating Tablets in the forum Suitability Petitions Archives</title>
				<link>https://fdapetitions.com/forums/topic/vesicare-solifenacin-orally-disintegrating-tablets/</link>
				<pubDate>Tue, 08 Oct 2019 17:44:57 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Vesicare®(solifenacin) Orally Disintegrating Tablets </b><br />
<b>Company: </b> Astellas<br />
<b>Petition Filer: </b> Intas<br />
<b>Petition Number(s): </b> 2019P-4645<br />
<b>Date of First Petition: </b> October 14, 2014<br />
<b>Responding Petitions: </b> None</p>
<p><b>Action Requested of Petition: </b> Petitioner seeks permission to file an ANDA for an orally disintegrating tablets 5 and 10mg. The&hellip;<span class="activity-read-more" id="activity-read-more-1289"><a href="https://fdapetitions.com/forums/topic/vesicare-solifenacin-orally-disintegrating-tablets/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">9144689486add8c7bf826e58e160adfc</guid>
				<title>gregoryglass started the topic Potassium Chloride in Dextrose and Sodium Chloride in the forum Safety Petitions Archives</title>
				<link>https://fdapetitions.com/forums/topic/potassium-chloride-in-dextrose-and-sodium-chloride/</link>
				<pubDate>Sat, 28 Sep 2019 10:55:08 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Potassium Chloride in Dextrose and Sodium Chloride </b><br />
<b>Company: </b> ICU Medical Inc<br />
<b>Petition Filer: </b> Fresenius Kabi<br />
<b>Petition Number(s): </b> 2019P-4523<br />
<b>Date of Petition: </b> September 27, 2019<br />
<b>Responding Petitions: </b></p>
<p><b>Action Requested by Petitioner: </b> Petitioner is requesting FDA to determine whether Potassium Chloride in Dextrose 5% and Sodium&hellip;<span class="activity-read-more" id="activity-read-more-1144"><a href="https://fdapetitions.com/forums/topic/potassium-chloride-in-dextrose-and-sodium-chloride/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">6d9d64803e722ea2f4b78b79eecfe2bd</guid>
				<title>gregoryglass started the topic Inderal®(propanolol) Tablets in the forum Product Petitions</title>
				<link>https://fdapetitions.com/forums/topic/inderal-propanolol-tablets/</link>
				<pubDate>Fri, 27 Sep 2019 14:14:14 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Inderal®(propanolol) Tablets</b> <b>Company: </b> Wyeth/IMPAX labs<b>Petition Filer: </b> Foley Lardner, a law firm<b>Petition Number(s): </b> 2019P-4515<b>Date of Petition: </b> September 26, 2019<b>Responding Petitions: </b> <b>Issue and Implication:</b> Whether FDA must designate a second Reference Standard.<b>Action Requested by Petitioner: </b> Petitioner is requesting the FDA&hellip;<span class="activity-read-more" id="activity-read-more-1120"><a href="https://fdapetitions.com/forums/topic/inderal-propanolol-tablets/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">8d8e436baf597649ddee1e2e85d722ee</guid>
				<title>gregoryglass started the topic Cleocin T®(clindamycin) Topical Solution in the forum Product Petitions</title>
				<link>https://fdapetitions.com/forums/topic/cleocin-t-clindamycin-topical-solution/</link>
				<pubDate>Thu, 26 Sep 2019 23:19:03 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Cleocin T®(clindamycin) Topical Solution</b><br />
<b>Company: </b> Pharmacia and Upjohn (Pfizer)<br />
<b>Petition Filer: </b> Macleods<br />
<b>Petition Number(s): </b> 2019P-4481<br />
<b>Date of Petition: </b> September 26, 2019<br />
<b>Responding Petitions: </b></p>
<p><b>Issue and Implication:</b> Whether FDA must designate a second Reference Standard.</p>
<p><b>Action Requested by Petitioner: </b> The Petitioner&hellip;<span class="activity-read-more" id="activity-read-more-1119"><a href="https://fdapetitions.com/forums/topic/cleocin-t-clindamycin-topical-solution/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">92bbb50107790dc09cb6f45bb9c382ca</guid>
				<title>gregoryglass started the topic Sinequan®(doxepin) Oral Concentrate in the forum Safety Petitions</title>
				<link>https://fdapetitions.com/forums/topic/sinequan-doxepin-oral-concentrate/</link>
				<pubDate>Tue, 24 Sep 2019 17:50:49 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Sinequan®(doxepin) Oral Concentrate </b> <b>Company: </b> Pfizer<b>Petition Filer: </b> Hibrow Healthcare<b>Petition Number(s): </b> 2019P-4424<b>Date of Petition: </b> September 23, 2019<b>Responding Petitions: </b> <b>Action Requested by Petitioner: </b> Petitioner is requesting FDA to determine whether Sinequan®(doxepin) Oral Concentrate (NDA 017516) was not being marketed for r&hellip;<span class="activity-read-more" id="activity-read-more-1143"><a href="https://fdapetitions.com/forums/topic/sinequan-doxepin-oral-concentrate/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">d46deda24a8e9b35e51a8c2ccd604895</guid>
				<title>gregoryglass started the topic Gris-Peg®(griseofulvin) Tablets in the forum Product Petitions</title>
				<link>https://fdapetitions.com/forums/topic/gris-peg-griseofulvin-tablets-d62/</link>
				<pubDate>Fri, 13 Sep 2019 15:59:43 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Gris-Peg®(griseofulvin) Tablets</b> <b>Company: </b> Valeant, Mountain<b>Petition Filer: </b> Hyman, Phelps, a law firm<b>Petition Number(s): </b> 2019P-4261<b>Date of Petition: </b> September 3, 2019<b>Responding Petitions: </b> <b>Issue and Implication:</b> Whether FDA must designate a second Reference Standard.<b>Action Requested by Petitioner: </b> The Petitioner would like to submit&hellip;<span class="activity-read-more" id="activity-read-more-1118"><a href="https://fdapetitions.com/forums/topic/gris-peg-griseofulvin-tablets-d62/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">f36361cc10fc85300763316a060108f6</guid>
				<title>gregoryglass started the topic Emend®(fosaprepitant) Injection in the forum Product Petitions</title>
				<link>https://fdapetitions.com/forums/topic/emend-fosaprepitant-injection-d97/</link>
				<pubDate>Tue, 10 Sep 2019 15:20:14 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Emend®(fosaprepitant) Injection</b> <b>Company: </b> Merck/Teva<b>Petition Filer: </b> Teva<b>Petition Number(s): </b> 2019P-4155<b>Date of Petition: </b> September 6, 2019<b>Responding Petitions: </b> <b>Issue and Implication:</b> Whether FDA must issue A ratings to 505(b)(2) NDA products that are similar to the reference list drug.<b>Action Requested by Petitioner: </b> The Petitioner is&hellip;<span class="activity-read-more" id="activity-read-more-1117"><a href="https://fdapetitions.com/forums/topic/emend-fosaprepitant-injection-d97/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">752cefbf3fe31abc6e8d73c99cc54902</guid>
				<title>gregoryglass started the topic Samsca®(tolvaptan) Tablets (Jynarque) in the forum Product Petitions</title>
				<link>https://fdapetitions.com/forums/topic/samsca-tolvaptan-tablets-jynarque/</link>
				<pubDate>Tue, 27 Aug 2019 11:57:18 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Samsca®(tolvaptan) Tablets (Jynarque) </b><br />
<b>Company: </b> Otuska<br />
<b>Petition Filer: </b> Otuska<br />
<b>Petition Number(s): </b> 2019P-4002<br />
<b>Date of Petition: </b> August 26, 2019<br />
<b>Responding Petitions: </b></p>
<p><b>Issue and Implication:</b> Whether FDA must apply the same REMS restrictions to a product with the same active ingredient but is not the same as the REMS&hellip;<span class="activity-read-more" id="activity-read-more-1116"><a href="https://fdapetitions.com/forums/topic/samsca-tolvaptan-tablets-jynarque/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">cea4573e753cf04deffc6727b2adbe92</guid>
				<title>gregoryglass started the topic Vasostrict®(vasopressin) Injection in the forum Suitability Petitions</title>
				<link>https://fdapetitions.com/forums/topic/vasostrict-vasopressin-injection-d0/</link>
				<pubDate>Thu, 22 Aug 2019 17:28:49 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Vasostrict®(vasopressin) Injection</b><br />
<b>Company: </b> Par<br />
<b>Petition Filer: </b> AuroMedics<br />
<b>Petition Number(s): </b> 2019P-3934<br />
<b>Date of First Petition: </b> August 21, 2019<br />
<b>Responding Petitions: </b></p>
<p><b>Action Requested of Petition: </b> The Petitioner would like to submit an ANDA and manufacture vasopressin injection of 20 units per mL (10 mL fill volume). This&hellip;<span class="activity-read-more" id="activity-read-more-1288"><a href="https://fdapetitions.com/forums/topic/vasostrict-vasopressin-injection-d0/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">930c0083e588ae07fad997123586f32b</guid>
				<title>gregoryglass started the topic Lidocaine Oral Solution 2% in the forum Product Petitions Archives</title>
				<link>https://fdapetitions.com/forums/topic/lidocaine-oral-solution-2/</link>
				<pubDate>Wed, 21 Aug 2019 14:23:07 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Lidocaine Oral Solution 2%</b><br />
<b>Company: </b> Various<br />
<b>Petition Filer: </b> Hymen Phelps, a law firm<br />
<b>Petition Number(s): </b> 2019P-3903<br />
<b>Date of Petition: </b> August 20, 2019<br />
<b>Responding Petitions: </b></p>
<p><b>Issue and Implication:</b> Whether FDA is required to designate a Reference Standard when the current Reference Standard is apparently not available.</p>
<p><b>Action&hellip;</b><span class="activity-read-more" id="activity-read-more-1114"><a href="https://fdapetitions.com/forums/topic/lidocaine-oral-solution-2/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">760685061a09bf9a92d31488c30ccb95</guid>
				<title>gregoryglass started the topic Glucophage®(metformin) Tablets in the forum Safety Petitions Archives</title>
				<link>http://fdapetitions.com/forums/topic/glucophage-metformin-tablets-d35/</link>
				<pubDate>Wed, 21 Aug 2019 14:11:29 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Glucophage®(metformin) Tablets</b><br />
<b>Company: </b> Bristol Myers Squibb<br />
<b>Petition Filer: </b> Harman Finochem<br />
<b>Petition Number(s): </b> 2019P-3877<br />
<b>Date of Petition: </b> August 20, 2019<br />
<b>Responding Petitions: </b></p>
<p><b>Action Requested by Petitioner: </b> The petitioner would like to FDA to determine whether Glucophage®(metformin) Tablets was removed from the market v&hellip;<span class="activity-read-more" id="activity-read-more-1287"><a href="http://fdapetitions.com/forums/topic/glucophage-metformin-tablets-d35/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">40cc4ec58849ee8595a56768d36521a3</guid>
				<title>gregoryglass started the topic Tenex®(guanfacine) Tablets in the forum Product Petitions Archives</title>
				<link>https://fdapetitions.com/forums/topic/tenex-guanfacine-tablets/</link>
				<pubDate>Fri, 16 Aug 2019 19:36:45 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Tenex®(guanfacine) Tablets</b><br />
<b>Company: </b> Promius/Amneal<br />
<b>Petition Filer: </b> Hymen Phelps<br />
<b>Petition Number(s): </b> 2019P-3803<br />
<b>Date of Petition: </b> August 13, 2019<br />
<b>Responding Petitions: </b></p>
<p><b>Issue and Implication:</b> Whether FDA is required to designate a Reference Standard when the current Reference Standard is apparently not available.</p>
<p><b>Action&hellip;</b><span class="activity-read-more" id="activity-read-more-1113"><a href="https://fdapetitions.com/forums/topic/tenex-guanfacine-tablets/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">9991a59560e6fab690a97f31aaf88bc5</guid>
				<title>gregoryglass started the topic Tegretol XR®(carbamazepine) Extended-release Tablets in the forum Product Petitions Archives</title>
				<link>http://fdapetitions.com/forums/topic/tegretol-xr-carbamazepine-extended-release-tablets/</link>
				<pubDate>Sun, 28 Jul 2019 17:20:55 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Tegretol XR®(carbamazepine) Extended-release Tablets</b><br />
<b>Company: </b> Novartis<br />
<b>Petition Filer: </b> Zydus<br />
<b>Petition Number(s): </b> 2019P-3545<br />
<b>Date of Petition: </b> July 26, 2019<br />
<b>Responding Petitions: </b> Teva</p>
<p><b>Issue and Implication:</b> Whether ANDA’s approved (or pending) must re-test their products if FDA issues a subsequent Draft Guidance for bi&hellip;<span class="activity-read-more" id="activity-read-more-1112"><a href="http://fdapetitions.com/forums/topic/tegretol-xr-carbamazepine-extended-release-tablets/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">6949ca8ba1e8fe78f90e39fb2137612e</guid>
				<title>gregoryglass started the topic Nix®(permethrin) Topical Lotion in the forum Safety Petitions Archives</title>
				<link>https://fdapetitions.com/forums/topic/nix-permethrin-topical-lotion/</link>
				<pubDate>Sat, 06 Jul 2019 15:04:35 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: </b> Nix®(permethrin) Topical Lotion<br />
<b>Company: </b> Glaxo Smithkline<br />
<b>Petition Filer: </b> Lachman Consultants<br />
<b>Petition Number(s): </b> 2019P-3232<br />
<b>Date of Petition: </b> Jujly 5, 2019<br />
<b>Responding Petitions: </b></p>
<p><b>Action Requested by Petitioner: </b> Petitioner is requesting FDA to determine whether Nix®(permethrin) Topical Lotion (NDA 019435) was removed from t&hellip;<span class="activity-read-more" id="activity-read-more-1142"><a href="https://fdapetitions.com/forums/topic/nix-permethrin-topical-lotion/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">ad1e81cad3a146b3f17f5fb0046ca52d</guid>
				<title>gregoryglass started the topic Neo Tect Kit®(for technetium Tc 99m depreotide) Injection in the forum Safety Petitions Archives</title>
				<link>https://fdapetitions.com/forums/topic/neo-tect-kit-for-technetium-tc-99m-depreotide-injection/</link>
				<pubDate>Thu, 27 Jun 2019 13:50:45 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: </b> Neo Tect Kit®(for technetium Tc 99m depreotide) Injection<br />
<b>Company: </b> Diatide<br />
<b>Petition Filer: </b> Andarix<br />
<b>Petition Number(s): </b> 2019P-3082<br />
<b>Date of Petition: </b> June 26, 2019<br />
<b>Responding Petitions: </b></p>
<p><b>Action Requested by Petitioner: </b> Petitioner is requesting FDA to determine whether Neo Tect Kit®(for technetium Tc 99m depreotide) Injection f&hellip;<span class="activity-read-more" id="activity-read-more-1141"><a href="https://fdapetitions.com/forums/topic/neo-tect-kit-for-technetium-tc-99m-depreotide-injection/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">1d29fa7765793ee04e99d667bbd1f605</guid>
				<title>gregoryglass started the topic Januvia®(sitagliptin) Tablets in the forum Suitability Petitions Archives</title>
				<link>https://fdapetitions.com/forums/topic/januvia-sitagliptin-tablets/</link>
				<pubDate>Wed, 26 Jun 2019 14:24:56 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Januvia®(sitagliptin) Tablets </b><br />
<b>Company: </b> Merck<br />
<b>Petition Filer: </b> Foley Lardner, a law firm<br />
<b>Petition Number(s): </b> 2019P-3024<br />
<b>Date of First Petition: </b> June 25, 2019<br />
<b>Responding Petitions: </b> None</p>
<p><b>Action Requested of Petition: </b> The Petitioner would like to submit an ANDA for a capsule dosage form of Januvia®(sitagliptin) Tablets (NDA 0&hellip;<span class="activity-read-more" id="activity-read-more-1286"><a href="https://fdapetitions.com/forums/topic/januvia-sitagliptin-tablets/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">4a90a096fa8e96311a436817336b922c</guid>
				<title>gregoryglass started the topic Xarelto®(rivaroxaban) Tablets in the forum Suitability Petitions Archives</title>
				<link>https://fdapetitions.com/forums/topic/xarelto-rivaroxaban-tablets/</link>
				<pubDate>Wed, 26 Jun 2019 14:20:37 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Xarelto®(rivaroxaban) Tablets </b><br />
<b>Company: </b> Janssen<br />
<b>Petition Filer: </b> Foley Lardner, a law firm<br />
<b>Petition Number(s): </b> 2019P-3022<br />
<b>Date of First Petition: </b> June 25, 2019<br />
<b>Responding Petitions: </b> None</p>
<p><b>Action Requested of Petition: </b> The Petitioner would like to submit an ANDA for a capsule dosage form of Xarelto®(rivaroxaban) Tablets (NDA 0&hellip;<span class="activity-read-more" id="activity-read-more-1140"><a href="https://fdapetitions.com/forums/topic/xarelto-rivaroxaban-tablets/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">3aace60f8189a4012e659f9289da3c17</guid>
				<title>gregoryglass started the topic Valsartan and N,N-Dimethylformamide in the forum Product Petitions</title>
				<link>https://fdapetitions.com/forums/topic/valsartan-and-n-n-dimethylformamide/</link>
				<pubDate>Fri, 14 Jun 2019 13:46:57 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Valsartan and N,N-Dimethylformamide</b><br />
<b>Company: </b> Various<br />
<b>Petition Filer: </b> Valisure<br />
<b>Petition Number(s): </b> 2019P-2869<br />
<b>Date of Petition: </b> June 13, 2019<br />
<b>Responding Petitions: </b></p>
<p><b>Issue and Implication:</b> Whether current FDA standards for daily intake of a known carcinogenic is sufficient to ensure safe use of medications.</p>
<p><b>Action Requested&hellip;</b><span class="activity-read-more" id="activity-read-more-1111"><a href="https://fdapetitions.com/forums/topic/valsartan-and-n-n-dimethylformamide/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">0d5aae4852de97e027cd8bf6b7e00a73</guid>
				<title>gregoryglass started the topic Delflex®(calcium chloride, et al) Injection in the forum Product Petitions</title>
				<link>https://fdapetitions.com/forums/topic/delflex-calcium-chloride-et-al-injection/</link>
				<pubDate>Fri, 14 Jun 2019 13:26:48 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Delflex®(calcium chloride, et al) Injection</b> <b>Company: </b> Fresenius Kabi<b>Petition Filer: </b> Fresenius Kabi<b>Petition Number(s): </b> 2019P-2853<b>Date of Petition: </b> June 13, 2019<b>Responding Petitions: </b> <b>Issue and Implication:</b> Whether a product has to be listed as a Reference Standard or Reference List Drug.<b>Action Requested by Petitioner: </b> Petitioner is&hellip;<span class="activity-read-more" id="activity-read-more-1110"><a href="https://fdapetitions.com/forums/topic/delflex-calcium-chloride-et-al-injection/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">559dda07fd8f92f8234bce22da68a05f</guid>
				<title>gregoryglass started the topic Viberzi®(eluxadoline) Tablets in the forum Product Petitions</title>
				<link>https://fdapetitions.com/forums/topic/viberzi-eluxadoline-tablets/</link>
				<pubDate>Sat, 25 May 2019 19:33:56 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Viberzi®(eluxadoline) Tablets</b> <b>Company: </b> Allergan<b>Petition Filer: </b> Allergan<b>Petition Number(s): </b> 2019P-2537<b>Date of Petition: </b> May 24, 2019<b>Responding Petitions: </b> <b>Issue and Implication:</b> Whether current FDA standards for an ANDA establishing bioequivalence is sufficient for locally-acting drugs.<b>Action Requested by Petitioner: </b> The Petitioner&hellip;<span class="activity-read-more" id="activity-read-more-1109"><a href="https://fdapetitions.com/forums/topic/viberzi-eluxadoline-tablets/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">14469ee64142baad26ab94992c4501ba</guid>
				<title>gregoryglass started the topic Depot Medroxyprogesterone Acetate and COC’s in the forum Product Petitions</title>
				<link>https://fdapetitions.com/forums/topic/depot-medroxyprogesterone-acetate-and-coc-s/</link>
				<pubDate>Sat, 11 May 2019 14:48:35 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Depot Medroxyprogesterone Acetate and COC’s</b><br />
<b>Company: </b> Various<br />
<b>Petition Filer: </b> Contraceptive Study Group<br />
<b>Petition Number(s): </b> 2019P-2289<br />
<b>Date of Petition: </b> May 10, 2019<br />
<b>Responding Petitions: </b></p>
<p><b>Issue and Implication:</b> Whether post-marketing surveillance is sufficient to ensure continued safe use of products on the market.</p>
<p><b>Action R&hellip;</b><span class="activity-read-more" id="activity-read-more-1108"><a href="https://fdapetitions.com/forums/topic/depot-medroxyprogesterone-acetate-and-coc-s/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">b4262dd8937f3a603e5a5af96fd70ecd</guid>
				<title>gregoryglass started the topic Efudex®(fluorouracil) Solution in the forum Product Petitions Archives</title>
				<link>https://fdapetitions.com/forums/topic/efudex-fluorouracil-solution/</link>
				<pubDate>Sat, 11 May 2019 14:33:03 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Efudex®(fluorouracil) Solution</b><br />
<b>Company: </b> Valeant<br />
<b>Petition Filer: </b> Encube<br />
<b>Petition Number(s): </b> 2019P-2074<br />
<b>Date of Petition: </b> May 10, 2019<br />
<b>Responding Petitions: </b></p>
<p><b>Issue and Implication:</b> Whether FDA must list a drug as a Reference List Drug.</p>
<p><b>Action Requested by Petitioner: </b> The petitioner is asking FDA to designate the Taro&hellip;<span class="activity-read-more" id="activity-read-more-1107"><a href="https://fdapetitions.com/forums/topic/efudex-fluorouracil-solution/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">c97a3a46af006a9d3144cd782737c63c</guid>
				<title>gregoryglass started the topic Oxitriptan in the forum Product Petitions</title>
				<link>https://fdapetitions.com/forums/topic/oxitriptan/</link>
				<pubDate>Fri, 03 May 2019 12:29:52 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Oxitriptan</b> <b>Company: </b> Various, API<b>Petition Filer: </b> Summit Health Pharmacy<b>Petition Number(s): </b> 2019P-2088<b>Date of Petition: </b> May 2, 2019<b>Responding Petitions: </b> <b>Issue and Implication:</b> Whether a compound used for a certain disease for decades qualifies it for  compounding under the 503A Bulks List.<b>Action Requested by Petitioner: </b> The Petitioner&hellip;<span class="activity-read-more" id="activity-read-more-1106"><a href="https://fdapetitions.com/forums/topic/oxitriptan/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">60c947d76ef9ef0a9ca112e0e33e0067</guid>
				<title>gregoryglass started the topic Levophed®(norephinephrine) Injection in the forum Suitability Petitions</title>
				<link>https://fdapetitions.com/forums/topic/levophed-norephinephrine-injection/</link>
				<pubDate>Thu, 02 May 2019 13:38:51 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Levophed®(norephinephrine) Injection</b> <b>Company: </b> Hospira<b>Petition Filer: </b> TechReg Services<b>Petition Number(s): </b> 2019P-2070<b>Date of First Petition: </b> May 1, 2019<b>Responding Petitions: </b> None<b>Action Requested of Petition: </b> “The undersigned requests that the Commissioner of the Food and Drug Administration determine whether the drug product No&hellip;<span class="activity-read-more" id="activity-read-more-1285"><a href="https://fdapetitions.com/forums/topic/levophed-norephinephrine-injection/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">0ec8502934cc83d82013ca01fef9d20d</guid>
				<title>gregoryglass started the topic Entresto®(sacubitril/valsartan) Tablets in the forum Product Petitions</title>
				<link>https://fdapetitions.com/forums/topic/entresto-sacubitril-valsartan-tablets/</link>
				<pubDate>Sat, 20 Apr 2019 15:09:45 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Entresto®(sacubitril/valsartan) Tablets </b><br />
<b>Company: </b> Novartis<br />
<b>Petition Filer: </b> Novartis<br />
<b>Petition Number(s): </b> 2019P-1893<br />
<b>Date of Petition: </b> April 19, 2019<br />
<b>Responding Petitions: </b></p>
<p><b>Issue and Implication:</b> Whether FDA Guidance regarding a showing of product sameness for an ANDA filer is sufficient to ensure product sameness.</p>
<p><b>Action&hellip;</b><span class="activity-read-more" id="activity-read-more-1105"><a href="https://fdapetitions.com/forums/topic/entresto-sacubitril-valsartan-tablets/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">46eaf784b795928f4b96189ac4984dec</guid>
				<title>gregoryglass started the topic Prolia®(denosumab) Injection in the forum Product Petitions Archives</title>
				<link>https://fdapetitions.com/forums/topic/prolia-denosumab-injection/</link>
				<pubDate>Thu, 18 Apr 2019 13:31:54 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Prolia®(denosumab) Injection</b><br />
<b>Company: </b> Amgen<br />
<b>Petition Filer: </b> Public Citizen<br />
<b>Petition Number(s): </b> 2019P-1818<br />
<b>Date of Petition: </b> April 17, 2019<br />
<b>Responding Petitions: </b> Amgen</p>
<p><b>Issue and Implication:</b> Whether additional evidence regarding the safety profile of a drug merits changes to the label.</p>
<p><b>Action Requested by Petitioner: </b> The&hellip;<span class="activity-read-more" id="activity-read-more-1104"><a href="https://fdapetitions.com/forums/topic/prolia-denosumab-injection/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">9088aeab0f474daa5fef0bfc773e98b5</guid>
				<title>gregoryglass started the topic Neostigmine Methylsulphate Injection in the forum Product Petitions Archives</title>
				<link>https://fdapetitions.com/forums/topic/neostigmine-methylsulphate-injection/</link>
				<pubDate>Sat, 06 Apr 2019 18:40:54 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Neostigmine Methylsulphate Injection</b><br />
<b>Company: </b> Fresenius Kabi<br />
<b>Petition Filer: </b> Nexsen Pruitt, a law firm<br />
<b>Petition Number(s): </b> 2019P-1636<br />
<b>Date of Petition: </b> April 5, 2019<br />
<b>Responding Petitions: </b></p>
<p><b>Issue and Implication:</b> Whether FDA must list a drug as a Reference List Drug.</p>
<p><b>Action Requested by Petitioner: </b> The petitioner is asking&hellip;<span class="activity-read-more" id="activity-read-more-1103"><a href="https://fdapetitions.com/forums/topic/neostigmine-methylsulphate-injection/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">976dbb53e3b3bccb10494d5a37368a5d</guid>
				<title>gregoryglass started the topic Dibenzyline®(phenoxybenzamine) Capsules in the forum Product Petitions Archives</title>
				<link>http://fdapetitions.com/forums/topic/dibenzyline-phenoxybenzamine-capsules/</link>
				<pubDate>Fri, 05 Apr 2019 14:09:03 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Dibenzyline®(phenoxybenzamine) Capsules</b><br />
<b>Company: </b> Concordia Pharmaceuticals<br />
<b>Petition Filer: </b> Aurobindo<br />
<b>Petition Number(s): </b> 2019P-1607<br />
<b>Date of Petition: </b> April 4, 2019<br />
<b>Responding Petitions: </b></p>
<p><b>Issue and Implication:</b> Whether FDA can designate a second Reference Standard.</p>
<p><b>Action Requested by Petitioner: </b> The Petitioner is asking&hellip;<span class="activity-read-more" id="activity-read-more-1102"><a href="http://fdapetitions.com/forums/topic/dibenzyline-phenoxybenzamine-capsules/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">5f52a31d211c46ccf8066bf0ad3fd5da</guid>
				<title>gregoryglass started the topic Mifeprex®(misoprostal) Tablets in the forum Product Petitions Archives</title>
				<link>https://fdapetitions.com/forums/topic/mifeprex-misoprostal-tablets/</link>
				<pubDate>Tue, 02 Apr 2019 15:11:23 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Mifeprex®(misoprostal) Tablets</b><br />
<b>Company: </b> Danco Laboratories<br />
<b>Petition Filer: </b> American Association of Pro-Life ObGyns<br />
<b>Petition Number(s): </b> 2019P-1534<br />
<b>Date of Petition: </b> April 1, 2019<br />
<b>Responding Petitions: </b></p>
<p><b>Issue and Implication:</b> Whether the REMS programs can be revised back to its original guidelines once modified.</p>
<p><b>Action&hellip;</b><span class="activity-read-more" id="activity-read-more-1101"><a href="https://fdapetitions.com/forums/topic/mifeprex-misoprostal-tablets/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">6c3b883c088b2e46c9d69bb9957086ed</guid>
				<title>gregoryglass started the topic List of Drug Bulk Substances and Compounding Pharmacies in the forum Issue Petitions</title>
				<link>https://fdapetitions.com/forums/topic/list-of-drug-bulk-substances-and-compounding-pharmacies/</link>
				<pubDate>Fri, 22 Mar 2019 21:53:14 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Issue: List of Drug Bulk Substances and Compounding Pharmacies</b> <b>Petition Filer: </b> American Association of Naturopathic Physicians (AANP)<b>Petition Number(s): </b> 2019P-1351<b>Date of Petition: </b> March 21, 2019<b>Responding Petitions: </b> <b>Issue and Implication:</b> Whether FDA can reconsider and re-write Final Rulemaking.<b>Action Requested by Petitioner: </b> The Petitioner&hellip;<span class="activity-read-more" id="activity-read-more-6"><a href="https://fdapetitions.com/forums/topic/list-of-drug-bulk-substances-and-compounding-pharmacies/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">bb9556d0f91152e577b3968073055cd7</guid>
				<title>gregoryglass started the topic Vimpat®(lacosamide) Oral Solution in the forum Suitability Petitions</title>
				<link>https://fdapetitions.com/forums/topic/vimpat-lacosamide-oral-solution/</link>
				<pubDate>Wed, 27 Feb 2019 14:53:03 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Vimpat®(lacosamide) Oral Solution </b> <b>Company: </b> USB Inc<b>Petition Filer: </b> Sunshine Lake Pharma Co<b>Petition Number(s): </b> 2019P-0915<b>Date of First Petition: </b> February 26, 2019<b>Responding Petitions: </b> None<b>Action Requested of Petition: </b> The Petitioner would like to submit an ANDA for a granules for oral solution form of lacosamide (10mg/mL). The RLD&hellip;<span class="activity-read-more" id="activity-read-more-1284"><a href="https://fdapetitions.com/forums/topic/vimpat-lacosamide-oral-solution/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">c30df9594e5ce4646f682736eaa82ef8</guid>
				<title>gregoryglass started the topic Goprelto®(cocaine) Nasal Spray in the forum Product Petitions Archives</title>
				<link>http://fdapetitions.com/forums/topic/goprelto-cocaine-nasal-spray/</link>
				<pubDate>Tue, 05 Feb 2019 16:13:23 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Goprelto®(cocaine) Nasal Spray</b><br />
<b>Company: </b> Genus Lifesciences<br />
<b>Petition Filer: </b> Genus Lifesciences<br />
<b>Petition Number(s): </b> 2019P-0538<br />
<b>Date of Petition: </b> February 4, 2019<br />
<b>Responding Petitions: </b> Lannett</p>
<p><b>Issue and Implication:</b> Whether an application (ANDA or 505(b)(2) filing) can be filed for five years during the New Chemical Exclusivity&hellip;<span class="activity-read-more" id="activity-read-more-1100"><a href="http://fdapetitions.com/forums/topic/goprelto-cocaine-nasal-spray/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">bd53d407758bbd9ececba6c538517b76</guid>
				<title>gregoryglass started the topic Methscopolamine Bromide Tablets in the forum Product Petitions Archives</title>
				<link>https://fdapetitions.com/forums/topic/methscopolamine-bromide-tablets/</link>
				<pubDate>Tue, 05 Feb 2019 15:56:38 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Methscopolamine Bromide Tablets</b><br />
<b>Company: </b> Unknown<br />
<b>Petition Filer: </b> Kulkarni Law Firm<br />
<b>Petition Number(s): </b> 2019P-0537<br />
<b>Date of Petition: </b> February 4, 2019<br />
<b>Responding Petitions: </b></p>
<p><b>Issue and Implication:</b> Whether an API or finished drug manufacturer must adhere to FDA Guidance.</p>
<p><b>Action Requested by Petitioner: </b> The Petitioner is&hellip;<span class="activity-read-more" id="activity-read-more-1099"><a href="https://fdapetitions.com/forums/topic/methscopolamine-bromide-tablets/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">06f927fe03b3f4b89199d2f4dd5a6d4b</guid>
				<title>gregoryglass started the topic Lidocaine Transdermals in the forum Product Petitions Archives</title>
				<link>https://fdapetitions.com/forums/topic/lidocaine-transdermals/</link>
				<pubDate>Wed, 30 Jan 2019 14:05:00 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Lidocaine Transdermals</b><br />
<b>Company: </b> Various<br />
<b>Petition Filer: </b> Scilex Pharmaceuticals<br />
<b>Petition Number(s): </b> 2019P-0417<br />
<b>Date of Petition: </b> January 29, 2019<br />
<b>Responding Petitions: </b></p>
<p><b>Issue and Implication:</b> Whether a product designated as Generally Recognized as Safe (GRAS) can be required to go through the NDA review process for certain&hellip;<span class="activity-read-more" id="activity-read-more-1098"><a href="https://fdapetitions.com/forums/topic/lidocaine-transdermals/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">523c7420f3efdaf1e6782897923b91dc</guid>
				<title>gregoryglass started the topic Bactrim®(sulfamethoxazole and trimethophrim) Oral Suspension in the forum Product Petitions</title>
				<link>https://fdapetitions.com/forums/topic/bactrim-sulfamethoxazole-and-trimethophrim-oral-suspension/</link>
				<pubDate>Fri, 18 Jan 2019 18:39:43 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Bactrim®(sulfamethoxazole and trimethophrim) Oral Suspension</b><br />
<b>Company: </b> Sun Pharmaceuticals<br />
<b>Petition Filer: </b> NaviSci Pte Ltd<br />
<b>Petition Number(s): </b> 2019P-0198<br />
<b>Date of Petition: </b> January 14, 2019<br />
<b>Responding Petitions: </b></p>
<p><b>Issue and Implication:</b> Whether FDA can designate a second Reference Standard.</p>
<p><b>Action Requested by Petitioner: </b> The&hellip;<span class="activity-read-more" id="activity-read-more-1097"><a href="https://fdapetitions.com/forums/topic/bactrim-sulfamethoxazole-and-trimethophrim-oral-suspension/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">f5b0f41cc440b4c8cef92ddebc261d55</guid>
				<title>gregoryglass started the topic Ketalar®(ketamine) Injection in the forum Suitability Petitions</title>
				<link>https://fdapetitions.com/forums/topic/ketalar-ketamine-injection/</link>
				<pubDate>Wed, 09 Jan 2019 12:59:31 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Ketalar®(ketamine) Injection</b><br />
<b>Company: </b> Par<br />
<b>Petition Filer: </b> Hospira<br />
<b>Petition Number(s): </b> 2019P-0114<br />
<b>Date of First Petition: </b> January 8, 2019<br />
<b>Responding Petitions: </b></p>
<p><b>Action Requested of Petition: </b> Petitioner is requesting that FDA allow it to submit an ANDA for a 200mg/2mL (100 mg/mL) dosage strength of ketamine hydrochloride&hellip;<span class="activity-read-more" id="activity-read-more-1283"><a href="https://fdapetitions.com/forums/topic/ketalar-ketamine-injection/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">f17fe848546944ce4d159d9c894dac54</guid>
				<title>gregoryglass started the topic Euthyrox®(levothyroxine) Tablets in the forum Product Petitions</title>
				<link>https://fdapetitions.com/forums/topic/euthyrox-levothyroxine-tablets/</link>
				<pubDate>Sat, 22 Dec 2018 17:49:31 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Euthyrox®(levothyroxine) Tablets</b><br />
<b>Company: </b> Provell Pharmaceuticals<br />
<b>Petition Filer: </b> Amneal<br />
<b>Petition Number(s): </b> 2018P-4832<br />
<b>Date of Petition: </b> December 21, 2018<br />
<b>Responding Petitions: </b> Provell Pharmaceuticals</p>
<p><b>Issue and Implication:</b> Whether a color coded tablets for a narrow therapeutic index drug is sufficient to merit an A&hellip;<span class="activity-read-more" id="activity-read-more-1096"><a href="https://fdapetitions.com/forums/topic/euthyrox-levothyroxine-tablets/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">8aede6f64f4e95019d0828737802ecb2</guid>
				<title>gregoryglass started the topic Glyrx-PF®(glycopyrrolate) Injection in the forum Product Petitions Archives</title>
				<link>https://fdapetitions.com/forums/topic/glyrx-pf-glycopyrrolate-injection/</link>
				<pubDate>Tue, 18 Dec 2018 15:29:40 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Glyrx-PF®(glycopyrrolate) Injection</b><br />
<b>Company: </b> Exela<br />
<b>Petition Filer: </b> Exela<br />
<b>Petition Number(s): </b> 2018P-4769<br />
<b>Date of Petition: </b> December 17, 2018<br />
<b>Responding Petitions: </b></p>
<p><b>Issue and Implication:</b> Whether a 505(b)(2) NDA can be AP rated to a product which is also discontinued.</p>
<p><b>Action Requested by Petitioner: </b> The Petitioner is&hellip;<span class="activity-read-more" id="activity-read-more-1095"><a href="https://fdapetitions.com/forums/topic/glyrx-pf-glycopyrrolate-injection/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">7074114eb08b09da55b24098062a10c2</guid>
				<title>gregoryglass started the topic Imvexxy&#x2122;(estradiol) Capsules in the forum Product Petitions</title>
				<link>https://fdapetitions.com/forums/topic/imvexxy-estradiol-capsules-2/</link>
				<pubDate>Fri, 14 Dec 2018 16:26:31 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Imvexxy&#x2122;(estradiol) Capsules</b><br />
<b>Company: </b> TherapeuticsMD<br />
<b>Petition Filer: </b> TherapeuticsMD<br />
<b>Petition Number(s): </b> 2018P-4714<br />
<b>Date of Petition: </b> December 12, 2018<br />
<b>Responding Petitions: </b> Teva</p>
<p><b>Issue and Implication:</b> Whether an ANDA needs to do additional bioequivalent testing for a locally acting product.</p>
<p><b>Action Requested by Petitioner: </b>&hellip;<span class="activity-read-more" id="activity-read-more-1094"><a href="https://fdapetitions.com/forums/topic/imvexxy-estradiol-capsules-2/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">a07e894ebc6b5f582fdb437bce65d11f</guid>
				<title>gregoryglass started the topic Lamisil®(terbinafine) Tablets in the forum Product Petitions</title>
				<link>https://fdapetitions.com/forums/topic/lamisil-terbinafine-tablets/</link>
				<pubDate>Fri, 30 Nov 2018 00:48:38 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Lamisil®(terbinafine) Tablets</b><br />
<b>Company: </b> Novartis/Aurobindo<br />
<b>Petition Filer: </b> Unichem Pharmaceuticals<br />
<b>Petition Number(s): </b> 2018P-4549<br />
<b>Date of Petition: </b> November 29, 2018<br />
<b>Responding Petitions: </b></p>
<p><b>Issue and Implication:</b> Whether FDA can designate a second Reference Standard.</p>
<p><b>Action Requested by Petitioner: </b> The Petitioner is asking&hellip;<span class="activity-read-more" id="activity-read-more-1093"><a href="https://fdapetitions.com/forums/topic/lamisil-terbinafine-tablets/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
					<item>
				<guid isPermaLink="false">7c16ae09332e47267ac236da08c6dded</guid>
				<title>gregoryglass started the topic Tygacil®(tigecycline) Injection in the forum Suitability Petitions</title>
				<link>https://fdapetitions.com/forums/topic/tygacil-tigecycline-injection-d94/</link>
				<pubDate>Fri, 16 Nov 2018 17:09:41 +0000</pubDate>

									<content:encoded><![CDATA[<p><b>Product: Tygacil®(tigecycline) Injection</b> <b>Company: </b> Prism<b>Petition Filer: </b> Freyr<b>Petition Number(s): </b> 2018P-4340<b>Date of First Petition: </b> November 14, 2018<b>Responding Petitions: </b> None<b>Action Requested of Petition: </b> Petitioner would like FDA to determine that tigecycline for injection, 50mg/vial containing 82.6mg of arginine as a stabilizing agent. The&hellip;<span class="activity-read-more" id="activity-read-more-1282"><a href="https://fdapetitions.com/forums/topic/tygacil-tigecycline-injection-d94/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
				
							</item>
		
	</channel>
</rss>